Clinical Trials Logo

Islet Cell Tumor clinical trials

View clinical trials related to Islet Cell Tumor.

Filter by:

NCT ID: NCT02038738 Not yet recruiting - Clinical trials for Neuroendocrine Carcinoma

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Start date: March 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.

NCT ID: NCT01374451 Completed - Islet Cell Tumor Clinical Trials

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

COOPERATE-1
Start date: June 2011
Phase: Phase 2
Study type: Interventional

This study will estimate the treatment effect of everolimus in combination with pasireotide LAR relative to everolimus alone on progression-free survival (PFS) in patients with advanced progressive PNET

NCT ID: NCT00830557 Recruiting - Pancreatic Cancer Clinical Trials

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders

Start date: October 1, 2000
Phase:
Study type: Observational

RATIONALE: Gathering medical information and collecting and storing samples of blood and tissue to test in the laboratory may help doctors develop better ways to screen people at risk for pancreatic cancer or other pancreatic disorders in the future. PURPOSE: This clinical trial is collecting medical information and tissue samples from patients with pancreatic cancer or other pancreatic disorders.

NCT ID: NCT00730483 Active, not recruiting - Metastatic Cancer Clinical Trials

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

Start date: February 2009
Phase: N/A
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Infusing doxorubicin beads into the liver, and blocking blood flow to the tumor, may keep doxorubicin near the tumor and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects of doxorubicin beads and to see how well they work in treating patients with unresectable liver metastases from neuroendocrine tumors.

NCT ID: NCT00602082 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Start date: August 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as capecitabine, streptozocin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving capecitabine together with streptozocin is more effective with or without cisplatin in treating neuroendocrine tumors. PURPOSE: This randomized phase II trial is studying giving capecitabine together with streptozocin to see how well it works compared with or without cisplatin in treating patients with unresectable or metastatic neuroendocrine tumors.

NCT ID: NCT00466856 Terminated - Clinical trials for Head and Neck Cancer

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Start date: December 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying how well internal radiation therapy works in treating patients with liver metastases from neuroendocrine tumors.

NCT ID: NCT00454376 Active, not recruiting - Lung Cancer Clinical Trials

Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

Start date: October 2006
Phase: Phase 4
Study type: Observational

RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects of treatment and improve the ability to plan treatment for patients with gastrointestinal-related neuroendocrine tumors. PURPOSE: This phase IV clinical trial is studying how well a disease-specific questionnaire works in assessing the quality of life of patients with gastrointestinal-related neuroendocrine tumors.

NCT ID: NCT00436735 Active, not recruiting - Colorectal Cancer Clinical Trials

Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors

Start date: September 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir in treating patients with metastatic, refractory, or recurrent solid tumors.

NCT ID: NCT00434109 Completed - Clinical trials for Neuroendocrine Tumor

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.

NCT ID: NCT00427349 Completed - Clinical trials for Gastrointestinal Carcinoid Tumor

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Start date: November 7, 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.